Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Increased by Gradient Investments LLC

Gradient Investments LLC raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 212.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,090 shares of the company’s stock after buying an additional 16,386 shares during the period. Gradient Investments LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $800,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TEVA. Cribstone Capital Management LLC raised its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the period. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares during the period. FNY Managed Accounts LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Sterling Investment Advisors Ltd. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. Finally, Financial Architects Inc raised its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares during the period. 56.27% of the stock is currently owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 18.59 on Tuesday. The stock has a 50 day moving average of $32.05 and a 200-day moving average of $32.28. Teva Pharmaceutical Industries Limited has a 1-year low of $18.50 and a 1-year high of $55.45. The firm has a market capitalization of $18.89 billion, a P/E ratio of 238.33 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same period in the previous year, the firm posted $1.25 EPS. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.44 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.83%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

COPYRIGHT VIOLATION WARNING: This report was originally reported by [[site]] and is the sole property of of [[site]]. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at [[permalink]].

Several analysts have issued reports on TEVA shares. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 price target on the stock. in a research report on Monday, May 22nd. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “neutral” rating in a research report on Friday. Mizuho reissued a “hold” rating and issued a $30.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 2nd. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. Finally, Deutsche Bank AG dropped their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries Limited has a consensus rating of “Hold” and an average target price of $39.19.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.